Intelligent AI, ML Algorithms Supporting COVID-19 Molecular Applications

The AI (Artificial Intelligence)-driven COVID-19 drug discovery is gaining increased popularity in the respiratory virus infection drugs market. Since the coronavirus has become an international health concern, there has been an unprecedented demand for drugs and vaccines. As such, AI holds promising potentials in quick identification of COVID-19 drugs. Thus, companies in the respiratory virus infection drugs market are collaborating with scientists and researchers to predict drugs and peptides that can be used as therapeutic medication for coronavirus treatment.

Pharmaceutical companies are increasing efforts to predict drugs directly from the sequences of infected patients, since they have a better affinity with the target. However, companies need to accelerate their testing capabilities in order to verify safety and feasibility to combat COVID-19. Intelligent algorithms based on machine learning (ML) and Big Data are supporting molecular applications.

respiratory virus infection drugs market infographic

To know the scope of our report Get a Sample on Respiratory Virus Infection Drugs Market

Rise in R&D Helps Address Low Solubility of Favipiravir in Aqueous Media

The respiratory virus infection drugs market is expected to surpass a value of US$ 82.4 Bn by the end of 2030. However, individuals are becoming increasingly aware about the disadvantages and side effects of influenza drugs, namely favipiravir and baloxavir. Pharma companies need to address low solubility of favipiravir in aqueous media, which may reduce its efficacy in vitro. This indicates that pharma companies need to increase their R&D activities to prevent adverse events of drugs.

Pharma companies are focusing on discoveries in influenza virus polymerase complex. It has been found that influenza viruses are severe human pathogens that pose as a persistent threat to public health. Hence, companies in the respiratory virus infection drugs market are capitalizing on this issue to increase their R&D in influenza virus polymerase complex.

Get a glimpse of the in-depth analysis through our Report Brochure

Efficient Drug Delivery via Nanotechnology Offers Growth Prospects in Clinical Practice

Companies in the respiratory virus infection drugs market are increasing their focus in nanomaterials designed for antiviral drug delivery of adenovirus infection. This has become important, since respiratory virus infections have become a global health problem causing a significant amount of mortality and morbidity in individuals. Emerging drug resistance and constant viral replication have led to the demand for nanotechnology in antiviral therapies, as nanomaterials offer unique physic-chemical properties ideal for the treatment of adenovirus infection.

Different nanomaterials such as nanosheres, liposomes, nanoparticles, nanogels, and the likes hold promising potentials for efficacious drug administration in order to improve patient outcomes. Companies in the respiratory virus infection drugs market are innovating in nanosuspensions and nanoemulsions to enable drug delivery of unique antiviral agents with prospects in clinical practice.

AI-based Multi-program Approach Enables Development of Successful Candidates for Antibiotic Resistance

The COVID-19 pandemic has brought startups in the respiratory virus infection drugs market under great emphasis. For instance, Vir Biotechnology— a specialist in immune therapeutics, is leveraging the advantages of AI and ML in influenza drug development. It has been found that infectious diseases have increased resistance to antibiotics. Startups in the respiratory virus infection drugs market are capitalizing on this opportunity to integrate AI and ML in common cold and influenza drug development.

In order to broaden their revenue streams, the U.S.-based tech startups are working on solutions to address antibiotic resistance in certain strains of influenza A, SARS-CoV-2, and tuberculosis. They are adopting a multi-program and multi-platform approach to develop successful candidates in order to tackle antibiotic resistance. Manufacturers are innovating in antibody platforms and T cell platforms to isolate rare antibodies and use them to boost the immune system.

State-of-art DAAs Holds Promising Potentials for RSV Treatment

The respiratory syncytial virus (RSV) is being associated with limited treatment options, resulting in millions of hospitalizations per year. Palivizumab, a monoclonal antibody, is considered as the gold standard for prophylaxis in high-risk infants. However, palivizumab and ribavirin are prone to limited efficacy and significant safety concerns. Hence, manufacturers in the respiratory virus infection drugs market are increasing their research in direct acting antiviral agents (DAAs) to target key steps in the viral life cycle.

It has been found that DAAs are producing landmark clinical studies, which involve nucleoside inhibitors. On the other hand, non-nucleoside inhibitors of replication are being reviewed in addition to inhibitors of other mechanisms. As such, pharma companies in the respiratory virus infection drugs market are taking giant strides in R&D pertaining to viral proteins or host cell factors for inhibition of viral replication.

Companies Forge Strategic Partnerships to Innovate in Treatment for LRTI in Infants

In vitro and in vivo model systems of the RSV disease are being highlighted in order to create novel drug targets. Companies in the respiratory virus infection drugs market are expanding their treatment options for lower respiratory tract infections (LRTI). For instance, Sanofi— a global biopharmaceutical company, announced that it received positive Phase 2b trial for nirsevimab, since it showed significant decline in medically attended lower respiratory tract infections. This involves increased hospitalization caused due to RSV in healthy preterm infants.

Single dose monoclonal antibodies are found to significantly reduce medically attended RSV LRTI infants through the full RSV season. Nirsevimad is being highly publicized as an extended half-life RSV monoclonal antibody. Companies are entering into strategic partnerships to innovate in treatments for LRTI in infants. Nirsevimab is gaining popularity as the new standard of care by offering innovative immunization for immediate and sustained protection for all infants during the first season of RSV.

Favipiravir and Boloxavir Approved for Influenza Treatment in Japan

Companies in the respiratory virus infection drugs market are increasing their production capabilities for anti-influenza drugs. Pharma companies in the respiratory virus infection drugs market are developing inhibitors of influenza virus polymerase, which are among the most promising types of drugs. Favipiravir and boloxavir are being approved for influenza treatment in Japan and the U.S. It has been found that favipiravir effectively and selectively inhibits the RNA dependent RNA polymerase of RNA viruses.

respiratory virus infection drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Sustainable pharmaceutical innovations in COVID-19 treatment hold promising potentials for other infectious diseases. Thus, the respiratory virus infection drugs market is estimated to grow at a healthy CAGR of ~7% during the assessment period. However, the issue of drug resistance in case of constant mutation of influenza virus is impacting market growth. Hence, pharma companies should conduct a sustained surveillance of the drug susceptibility of influenza viruses. Moreover, limited efficacy of influenza vaccines and drug resistance from small molecule antiviral drugs have led to the demand for new antivirals with novel mode of action.

Respiratory Virus Infection Drugs Market: Overview​

  • According to Transparency Market Research’s latest report on the global respiratory virus infection drugs market for the historical period 20182019 and forecast period of 20202030, increase in focus on research & development is projected to drive the global respiratory virus infection drugs market
  • According to the report, the global respiratory virus infection drugs market was valued over US$ 38.6 Bn in 2019 and is anticipated to expand at a CAGR of ~7% from 2020 to 2030
  • Respiratory virus infection is a type of infection of the airway and lungs caused by different types of virus. Viral respiratory infections (VRIs) include cold, flu, and bronchiolitis. Several medications are used for the treatment of respiratory virus infections including prescription and OTC.​

Surge in Adoption of Combination Therapy to Drive Respiratory Virus Infection Drugs Market

  • Adoption of combination therapy is increasing, as it is more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.
  • Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory diseases such as asthma and COPD
  • Steady rise in prevalence of respiratory virus infections across the globe leads to high demand for advanced therapeutics. This, in turn, is expected to propel the global respiratory virus infection drugs market.

Increase in Expenditure on Healthcare and Immunization Augments Respiratory Virus Infection Drugs Market

  • Rise in healthcare expenditure increases the availability of better healthcare infrastructure, improves operational efficiency, and encourages awareness programs related to vaccination and treatment of diseases
  • According to the World Health Organization, expenditure on immunization in 72 countries across the globe increased between 2005 and 2015. According to the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. in 2017 was 17.9% of the GDP.

Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Market

  • Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. It hampers the revenue generated from the sale of branded drugs and can affect the market share of a company. This, in turn, is likely to hamper the growth of the global respiratory virus infection drugs market.
  • For instance, AstraZeneca’s Symbicort Turbuhaler went off-patent in Europe in 2019, whereas, GlaxoSmithKline plc’s Qvar, Singulair, and Diskus device patents have expired. This is projected to lead to dramatic decline in sales, thereby affecting market positions of the companies.

Respiratory Virus Infection Drugs Market: Competition Landscape

  • This report profiles major players operating in the global respiratory virus infection drugs market based on various attributes and recent developments
  • The global respiratory virus infection drugs market is highly fragmented, with the presence of large number of global as well as regional players
  • Leading players operating in the global respiratory virus infection drugs market include
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Cipla, Inc.
    • CHIESI Farmaceutici S.p.A.
    • Orion Corporation

Respiratory Virus Infection Drugs Treatment Market: Key Developments

  • Leading players in the global respiratory virus infection drugs market engage in regulatory approvals, development of technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at addressing unmet needs in the global respiratory virus infection drugs market, strengthening the product portfolio and investments in research & development. A few expansion strategies adopted by players in the global respiratory virus infection drugs market are:
  • In May 2019, Merck & Co., Inc. announced plans to invest US$ 1 Bn in its manufacturing facility in Elkton, Virginia, the U.S.
  • In September 2018, AstraZeneca and its partner Amgen, Inc. (Amgen) announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for tezepelumab for the treatment of severe asthma patients without an eosinophilic phenotype. This breakthrough therapy enabled the company to enhance its respiratory portfolio and treat a diverse population having severe asthma, including those ineligible for currently approved biologic therapies.
  • In March 2018, Boehringer Ingelheim International GmbH announced that the indication for use of SPIRIVA Respimat (tiotropium Respimat) was extended. Regulatory authorities of the EU had accepted the add-on bronchodilator treatment therapy in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the past year.
  • The report on the global respiratory virus infection drugs market discussed individual strategies, followed by company profiles of manufacturers of respiratory virus infection drugs products
  • The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global respiratory virus infection drugs market

Respiratory Virus Infection Drugs Market – Segmentation

Drug Type
  • Antibiotics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Cough Suppressants
  • Nasal Decongestants
  • Others
Infection Type
  • Respiratory Syncytial Virus (RSV) Infection
  • Influenza Virus Infection
  • Parainfluenza Virus Infection
  • Adenovirus Infection
  • Rhinovirus Infection
  • Others
Route of Administration
  • Oral
  • Parenteral
Mode of Purchase
  • Prescription-based Drugs
  • Over-the-counter Drugs
Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Clinics
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Respiratory virus infection drugs market is expected to surpass a value of US$ 82.4 Bn by the end of 2030

Respiratory virus infection drugs market is projected to expand at a CAGR of ~7% from 2020 to 2030

Respiratory virus infection drugs market is driven by increase in focus on research & development, steady rise in prevalence of respiratory virus infections across the globe

North America dominated the global respiratory virus infection drugs market and the trend is anticipated to continue during the forecast period

Key players in the global respiratory virus infection drugs market include GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Virus Infection Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, 2018–2030

5. Key Insights

    5.1. Healthcare Industry Overview

    5.2. Pipeline Analysis (asthma and COPD)

    5.3. Regulatory Scenario 

    5.4. Disease Prevalence Rate in Key Countries

    5.5. Key Market Events

    5.6. COVID-19 Pandemic Impact on Industry

6. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2018–2030

        6.3.1. Antibiotics

        6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

        6.3.3. Cough Suppressants

        6.3.4. Nasal Decongestants

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug Type

7. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Infection Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Infection Type, 2018–2030

        7.3.1. Respiratory Syncytial Virus (RSV) Infection

        7.3.2. Influenza Virus Infection

        7.3.3. Parainfluenza Virus Infection

        7.3.4. Adenovirus Infection

        7.3.5. Rhinovirus Infection

        7.3.6. Others

    7.4. Market Attractiveness Analysis, by Infection Type

8. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Route of Administration, 2018–2030

        8.3.1. Oral

        8.3.2. Parenteral

    8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Mode of Purchase

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Mode of Purchase, 2018–2030

        9.3.1. Prescription-based Drugs

        9.3.2. Over-the-Counter Drugs

    9.4. Market Attractiveness Analysis, by Mode of Purchase

10. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Distribution Channel

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Market Value Forecast, by Distribution Channel, 2018–2030

        10.3.1. Hospital Pharmacies

        10.3.2. Drug Stores

        10.3.3. Retail Pharmacies

        10.3.4. Clinics

        10.3.5. Others

    10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Region

    11.1. Key Findings

    11.2. Market Value Forecast, by Region

        11.2.1. North America 

        11.2.2. Europe 

        11.2.3. Asia Pacific 

        11.2.4. Latin America 

        11.2.5. Middle East & Africa 

    11.3. Market Attractiveness Analysis, by Country/Region

12. North America Respiratory Virus Infection Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2018–2030

        12.2.1. Antibiotics

        12.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

        12.2.3. Cough Suppressants

        12.2.4. Nasal Decongestants

        12.2.5. Others

    12.3. Market Value Forecast, by Infection Type, 2018–2030

        12.3.1. Respiratory syncytial viruses (RSV) Infection

        12.3.2. Influenza Virus Infection

        12.3.3. Parainfluenza Virus Infection

        12.3.4. Adenovirus Infection

        12.3.5. Rhinovirus Infection

        12.3.6. Others

    12.4. Market Value Forecast, by Route of Administration, 2018–2030

        12.4.1. Oral

        12.4.2. Parenteral

    12.5. Market Value Forecast, by Mode of Purchase, 2018–2030

        12.5.1. Prescription-based Drugs

        12.5.2. Over-the-Counter Drugs

    12.6. Market Value Forecast, by Distribution Channel, 2018–2030

        12.6.1. Hospital Pharmacies

        12.6.2. Drug Stores

        12.6.3. Retail Pharmacies

        12.6.4. Clinics

        12.6.5. Others

    12.7. Market Value Forecast, by Country, 2018–2030

        12.7.1. U.S.

        12.7.2. Canada

    12.8. Market Attractiveness Analysis 

        12.8.1. By Drug Type

        12.8.2. By Infection Type

        12.8.3. By Route Of Administration

        12.8.4. By Mode of Purchase

        12.8.5. By Distribution Channel

        12.8.6. By Country

13. Europe Respiratory Virus Infection Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2018–2030

        13.2.1. Antibiotics

        13.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

        13.2.3. Cough Suppressants

        13.2.4. Nasal Decongestants

        13.2.5. Others

    13.3. Market Value Forecast, by Infection Type, 2018–2030

        13.3.1. Respiratory Syncytial Virus (RSV) Infection

        13.3.2. Influenza Virus Infection

        13.3.3. Parainfluenza Virus Infection

        13.3.4. Adenovirus Infection

        13.3.5. Rhinovirus Infection

        13.3.6. Others

    13.4. Market Value Forecast, by Route of Administration, 2018–2030

        13.4.1. Oral

        13.4.2. Parenteral

    13.5. Market Value Forecast, by Mode of Purchase, 2018–2030

        13.5.1. Prescription-based Drugs

        13.5.2. Over-the-Counter Drugs

    13.6. Market Value Forecast, by Distribution Channel, 2018–2030

        13.6.1. Hospital Pharmacies

        13.6.2. Drug Stores

        13.6.3. Retail Pharmacies

        13.6.4. Clinics

        13.6.5. Others

    13.7. Market Value Forecast, by Country/Sub-region, 2018–2030

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Spain

        13.7.5. Italy

        13.7.6. Rest of Europe

    13.8. Market Attractiveness Analysis 

        13.8.1. By Drug Type

        13.8.2. By Infection Type

        13.8.3. By Route Of Administration

        13.8.4. By Mode of Purchase

        13.8.5. By Distribution Channel

        13.8.6. By Country/Sub-region

14. Asia Pacific Respiratory Virus Infection Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Type, 2018–2030

        14.2.1. Antibiotics

        14.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

        14.2.3. Cough Suppressants

        14.2.4. Nasal Decongestants

        14.2.5. Others

    14.3. Market Value Forecast, by Infection Type, 2018–2030

        14.3.1. Respiratory Syncytial Virus (RSV) Infection

        14.3.2. Influenza Virus Infection

        14.3.3. Parainfluenza Virus Infection

        14.3.4. Adenovirus Infection

        14.3.5. Rhinovirus Infection

        14.3.6. Others

    14.4. Market Value Forecast, by Route Of Administration, 2018–2030

        14.4.1. Oral

        14.4.2. Parenteral

    14.5. Market Value Forecast, by Mode of Purchase, 2018–2030

        14.5.1. Prescription-based Drugs

        14.5.2. Over-the-Counter Drugs

    14.6. Market Value Forecast, by Distribution Channel, 2018–2030

        14.6.1. Hospital Pharmacies

        14.6.2. Drug Stores

        14.6.3. Retail Pharmacies

        14.6.4. Clinics

        14.6.5. Others

    14.7. Market Value Forecast, by Country/Sub-region, 2018–2030

        14.7.1. China

        14.7.2. Japan

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. Rest of Asia Pacific

    14.8. Market Attractiveness Analysis 

        14.8.1. By Drug Type

        14.8.2. By Infection Type

        14.8.3. By Route of Administration

        14.8.4. By Mode of Purchase

        14.8.5. By Distribution Channel

        14.8.6. By Country/Sub-region

15. Latin America Respiratory Virus Infection Drugs Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Drug Type, 2018–2030

        15.2.1. Antibiotics

        15.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

        15.2.3. Cough Suppressants

        15.2.4. Nasal Decongestants

        15.2.5. Others

    15.3. Market Value Forecast, by Infection Type, 2018–2030

        15.3.1. Respiratory Syncytial Virus (RSV) Infection

        15.3.2. Influenza Virus Infection

        15.3.3. Parainfluenza Virus Infection

        15.3.4. Adenovirus Infection

        15.3.5. Rhinovirus Infection

        15.3.6. Others

    15.4. Market Value Forecast, by Route of Administration, 2018–2030

        15.4.1. Oral

        15.4.2. Parenteral

    15.5. Market Value Forecast, by Mode of Purchase, 2018–2030

        15.5.1. Prescription-based Drugs

        15.5.2. Over-the-Counter Drugs

    15.6. Market Value Forecast, by Distribution Channel, 2018–2030

        15.6.1. Hospital Pharmacies

        15.6.2. Drug Stores

        15.6.3. Retail Pharmacies

        15.6.4. Clinics

        15.6.5. Others

    15.7. Market Value Forecast, by Country/Sub-region, 2018–2030

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Rest of Latin America

    15.8. Market Attractiveness Analysis 

        15.8.1. By Drug Type

        15.8.2. By Infection Type

        15.8.3. By Route of Administration

        15.8.4. By Mode of Purchase

        15.8.5. By Distribution Channel

        15.8.6. By Country/Sub-region

16. Middle East & Africa Respiratory Virus Infection Drugs Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast, by Drug Type, 2018–2030

        16.2.1. Antibiotics

        16.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

        16.2.3. Cough Suppressants

        16.2.4. Nasal Decongestants

        16.2.5. Others

    16.3. Market Value Forecast, by Infection Type, 2018–2030

        16.3.1. Respiratory Syncytial Virus (RSV) Infection

        16.3.2. Influenza Virus Infection

        16.3.3. Parainfluenza Virus Infection

        16.3.4. Adenovirus Infection

        16.3.5. Rhinovirus Infection

        16.3.6. Others

    16.4. Market Value Forecast, by Route of Administration, 2018–2030

        16.4.1. Oral

        16.4.2. Parenteral

    16.5. Market Value Forecast, by Mode of Purchase, 2018–2030

        16.5.1. Prescription-based Drugs

        16.5.2. Over-the-Counter Drugs

    16.6. Market Value Forecast, by Distribution Channel, 2018–2030

        16.6.1. Hospital Pharmacies

        16.6.2. Drug Stores

        16.6.3. Retail Pharmacies

        16.6.4. Clinics

        16.6.5. Others

    16.7. Market Value Forecast, by Country/Sub-region, 2018–2030

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Rest of Middle East & Africa

    16.8. Market Attractiveness Analysis 

        16.8.1. By Drug Type

        16.8.2. By Infection Type

        16.8.3. By Route of Administration

        16.8.4. By Mode of Purchase

        16.8.5. By Distribution Channel

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player - Competition Matrix (by tier and size of companies)

    17.2. Market Share Analysis/Ranking, by Company, 2019

    17.3. Company Profiles

        17.3.1. GlaxoSmithKline plc 

            17.3.1.1. Company Overview

            17.3.1.2. Company Financials

            17.3.1.3. Growth Strategies

            17.3.1.4. SWOT Analysis

        17.3.2. Merck & Co., Inc. 

            17.3.2.1. Company Overview

            17.3.2.2. Company Financials

            17.3.2.3. Growth Strategies

            17.3.2.4. SWOT Analysis

        17.3.3. AstraZeneca

            17.3.3.1. Company Overview

            17.3.3.2. Company Financials

            17.3.3.3. Growth Strategies

            17.3.3.4. SWOT Analysis

        17.3.4. Boehringer Ingelheim International GmbH 

            17.3.4.1. Company Overview

            17.3.4.2. Company Financials

            17.3.4.3. Growth Strategies

            17.3.4.4. SWOT Analysis

        17.3.5. F. Hoffmann-La Roche Ltd. 

            17.3.5.1. Company Overview

            17.3.5.2. Company Financials

            17.3.5.3. Growth Strategies

            17.3.5.4. SWOT Analysis

        17.3.6. Teva Pharmaceutical Industries Ltd. 

            17.3.6.1. Company Overview

            17.3.6.2. Company Financials

            17.3.6.3. Growth Strategies

            17.3.6.4. SWOT Analysis

        17.3.7. Sanofi

            17.3.7.1. Company Overview

            17.3.7.2. Company Financials

            17.3.7.3. Growth Strategies

            17.3.7.4. SWOT Analysis

        17.3.8. Cipla, Inc. 

            17.3.8.1. Company Overview

            17.3.8.2. Company Financials

            17.3.8.3. Growth Strategies

            17.3.8.4. SWOT Analysis

        17.3.9. CHIESI Farmaceutici S.p.A. 

            17.3.9.1. Company Overview

            17.3.9.2. Company Financials

            17.3.9.3. Growth Strategies

            17.3.9.4. SWOT Analysis

        17.3.10. Orion Corporation

            17.3.10.1. Company Overview

            17.3.10.2. Growth Strategies

            17.3.10.3. SWOT Analysis

List of Tables

Table 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 02: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 03: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 04: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 05: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 09: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 10: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 11: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 12: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 15: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 16: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 18: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 21: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 22: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 24: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 27: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 28: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 30: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 33: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 34: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 36: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Respiratory Virus Infection Drugs Market Value Share, by Drug Type, 2019

Figure 03: Global Respiratory Virus Infection Drugs Market Value Share, by Infection Type, 2019

Figure 04: Global Respiratory Virus Infection Drugs Market Value Share, by Route of Administration, 2019

Figure 05: Global Respiratory Virus Infection Drugs Market Value Share, by Mode of Purchase, 2019

Figure 06: Global Respiratory Virus Infection Drugs Market Value Share, by Distribution Channel, 2019

Figure 07: Global Respiratory Virus Infection Drugs Market Value Share, by Region, 2019

Figure 08: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Drug Type, 2019 and 2030

Figure 09: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 10: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Antibiotics, 2018–2030

Figure 11: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2018–2030

Figure 12: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Cough Suppressants, 2018–2030

Figure 13: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Nasal Decongestants, 2018–2030

Figure 14: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030

Figure 15: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Infection Type, 2019 and 2030

Figure 16: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 17: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Respiratory Syncytial Virus (RSV) Infection, 2018–2030

Figure 18: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Influenza Virus Infection, 2018–2030

Figure 19: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Parainfluenza Virus Infection, 2018–2030

Figure 20: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Adenovirus Infection, 2018–2030

Figure 21: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Rhinovirus Infection, 2018–2030

Figure 22: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030

Figure 23: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 24: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 25: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Oral, 2018–2030

Figure 26: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Parenteral, 2018–2030

Figure 27: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Mode of Purchase, 2019 and 2030

Figure 28: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 29: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Prescription-based Drugs, 2018–2030

Figure 30: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Over-the-Counter Drugs, 2018–2030

Figure 31: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 32: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 33: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 34: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Drug Stores, 2018–2030

Figure 35: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 36: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Clinics, 2018–2030

Figure 37: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030

Figure 38: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Region, 2019 and 2030

Figure 39: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Region

Figure 40: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 41: North America Respiratory Virus Infection Drugs Market Value Share (%), by Country, 2019 and 2030

Figure 42: North America Respiratory Virus Infection Drugs Market Attractiveness, by Country, 2020–2030

Figure 43: North America Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 44: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 45: North America Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 46: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 47: North America Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 48: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 49: North America Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 50: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 51: North America Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 52: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 53: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 55: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 56: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 57: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 58: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 59: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 60: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 61: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 62: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 63: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 64: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 65: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 66: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 67: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 68: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 69: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 70: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 71: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 72: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 73: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 74: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 75: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 76: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 77: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 78: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 79: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 80: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 81: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 82: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 83: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 84: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 85: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 86: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 87: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 88: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 89: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 90: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 91: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 92: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 93: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 94: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 95: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 96: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 97: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 98: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 99: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 100: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 101: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 102: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 103: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 104: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Respiratory Virus Infection Drugs Market